Inactive Instrument

DUCAT VENTURES London S.E.

Equities

Biotechnology & Medical Research

End-of-day quote London S.E. Other stock markets
- ^GBX	-

Mar. 25	OptiBiotix Health raises GBP1.4 million to invest in "driving sales"	AN
Mar. 25	OptiBiotix Health Raises GBP1.4 Million via Share Placing, Subscription	MT

OptiBiotix Health : Tim Tutton to join Bristol Water board

December 19, 2014 at 05:01 am EST

By BFN News | 08:43 AM | Friday 19 December, 2014

Bristol Water has appointed Tim Tutton as a non-executive director with effect from 1 January. Tutton is an independent economic consultant specialising in economic regulation, especially in the energy sector. He is an Honorary University Fellow in the College of Life and Environmental Sciences at Exeter University. He was appointed to the panel at the Competition and Markets Authority (CMA) in 2013. At 8:43am: (LON:BWRA) Bristol Water PLC share price was 0p at 150.5p Story provided by StockMarketWire.

distributed by

Latest news about DUCAT VENTURES

OptiBiotix Health raises GBP1.4 million to invest in "driving sales"	Mar. 25	AN
OptiBiotix Health Raises GBP1.4 Million via Share Placing, Subscription	Mar. 25	MT
EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal	Mar. 13	AN
OptiBiotix Health plc Signs Partnership Agreement with Dr Morepen Ltd	Mar. 13	CI
OptiBiotix products return to sales growth as pipeline strong	Feb. 27	AN
OptiBiotix in discussions for launch of SweetBiotix	Jan. 30	AN
OptiBiotix Health to Launch Sports Nutrition Product in Europe	Jan. 15	MT
OptiBiotix's LeanBiome to be launched under MuscleTech	Jan. 15	AN
OptiBiotix Health PlcAnnounces Launch of LeanBiome in Muscletech	Jan. 15	CI
OptiBiotix names Croda's Graham Myers as finance director	Dec. 04	AN
UK's Optibiotix Health Appoints Finance Director	Dec. 04	MT
Optibiotix Health plc Appoints Graham Myers as Finance Director	Dec. 04	CI
Scancell trial progresses; OptiBiotix inks new deal	Nov. 28	AN
Optibiotix Health plc Signs an Agreement with Ravenswood Ingredients Pty Ltd ("Ravenswood") for the Distribution of Slimbiome®In Australia and New Zealand	Nov. 28	CI
EARNINGS AND TRADING: Victorian Plumbing profit up; Duke revenue dips	Nov. 22	AN
OptiBiotix says market still "volatile" but partner sales improving	Nov. 01	AN
OptiBiotix Health Expands Network in US, Asia	Nov. 01	MT
OptiBiotix Health Secures License Deal for Tata Chemicals' Fossence; Shares Jump	23-10-23	MT
OptiBiotix adds Tata Chemicals ingredient to obesity product in India	23-10-23	AN
EARNINGS: Safestyle suffers amid "difficult" trading conditions	23-09-27	AN
Earnings Flash (OPTI.L) OPTIBIOTIX HEALTH Posts H1 Revenue GBP351,000	23-09-27	MT
Earnings Flash (OPTI.L) OPTIBIOTIX HEALTH Reports H1 Loss GBX-2.09	23-09-27	MT
OptiBiotix Health Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-27	CI
OptiBiotix Health to Launch Three Products in FY24; Shares Jump 18%	23-09-22	MT
FTSE 100 picks up on hopes BoE rates have peaked	23-09-22	AN

Chart DUCAT VENTURES

Duration

Period

More charts

Company Profile

OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiome, SlimBiome Medical and WellBiome.

Sector

Biotechnology & Medical Research

Calendar

2024-06-25 - Q4 2023 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs